Cargando…

Central Versus Peripheral Drug Exposure Ratio, a Key Differentiator for Siponimod Over Fingolimod?

INTRODUCTION: Siponimod, a potent and selective sphingosine-1-phosphate (S1P(1,5)) agonist, is the only therapeutic agent that has shown efficacy against disability progression, decline in cognitive processing speed, total brain volume loss, gray matter atrophy and signs of demyelination in patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bigaud, Marc, Ramseier, Pamela, Tisserand, Sarah, Lang, Meike, Urban, Beatrice, Beerli, Christian, Karlsson, Göril
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10310674/ https://www.ncbi.nlm.nih.gov/pubmed/37195409 http://dx.doi.org/10.1007/s40120-023-00487-4

Ejemplares similares

Siponimod (BAF312) penetrates, distributes, and acts in the central nervous system: Preclinical insights
por: Bigaud, Marc, et al.
Publicado: (2021)

Increased Remyelination and Proregenerative Microglia Under Siponimod Therapy in Mechanistic Models
por: Dietrich, Michael, et al.
Publicado: (2022)

COVID-19 Infection in Fingolimod- or Siponimod-Treated Patients: Case Series
por: Sullivan, Roseanne, et al.
Publicado: (2021)

Impact of Siponimod on Enteric and Central Nervous System Pathology in Late-Stage Experimental Autoimmune Encephalomyelitis
por: Weier, Alicia, et al.
Publicado: (2022)

Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis
por: Cree, Bruce AC, et al.
Publicado: (2020)

The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing–Remitting and Secondary Progressive Multiple Sclerosis
por: Vališ, Martin, et al.
Publicado: (2023)

Disease reactivation in a patient with secondary progressive multiple sclerosis after switching treatment from fingolimod to siponimod
por: Senzaki, Kensuke, et al.
Publicado: (2021)

Disease Reactivation in Secondary Progressive Multiple Sclerosis Patients Switching from Fingolimod to Siponimod: A Case Series
por: Abbadessa, Gianmarco, et al.
Publicado: (2022)

Siponimod for multiple sclerosis
Publicado: (2021)

Does Siponimod Exert Direct Effects in the Central Nervous System?
por: Kipp, Markus
Publicado: (2020)

Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial
por: Arnold, Douglas L, et al.
Publicado: (2022)

Siponimod ameliorates experimental autoimmune neuritis
por: Uchi, Takafumi, et al.
Publicado: (2023)

Prospects of siponimod in secondary progressive multiple sclerosis
por: McGinley, Marisa, et al.
Publicado: (2018)

Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study
por: Gold, Ralf, et al.
Publicado: (2022)

Mechanism of Siponimod: Anti-Inflammatory and Neuroprotective Mode of Action
por: Behrangi, Newshan, et al.
Publicado: (2019)

Siponimod: A Review in Secondary Progressive Multiple Sclerosis
por: Scott, Lesley J.
Publicado: (2020)

Determination of Seminal Concentration of Fingolimod and Fingolimod‐Phosphate in Multiple Sclerosis Patients Receiving Chronic Treatment With Fingolimod
por: David, Olivier J., et al.
Publicado: (2017)

A Swiss real world best practice experience in three different clinical settings of the 6 hour fingolimod first dose observation procedure
por: Ramseier, Simon P, et al.
Publicado: (2015)

Correction to: Siponimod: A Review in Secondary Progressive Multiple Sclerosis
por: Scott, Lesley J.
Publicado: (2021)

Migraine, interferon β1a and siponimod immunomodulator therapies
por: Dahaba, Ashraf A., et al.
Publicado: (2022)

Siponimod Modulates the Reaction of Microglial Cells to Pro-Inflammatory Stimulation
por: Gruchot, Joel, et al.
Publicado: (2022)

Long-term real-world effectiveness and safety of fingolimod over 5 years in Germany
por: Ziemssen, Tjalf, et al.
Publicado: (2022)

Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis
por: Gentile, Antonietta, et al.
Publicado: (2016)

Impact of siponimod on vaccination response in a randomized, placebo-controlled study
por: Ufer, Mike, et al.
Publicado: (2017)

The Two Sides of Siponimod: Evidence for Brain and Immune Mechanisms in Multiple Sclerosis
por: Cohan, Stanley L., et al.
Publicado: (2022)

Fingolimod Modulates Peripheral Effector and Regulatory T Cells in MS Patients
por: Serpero, Laura D., et al.
Publicado: (2013)

Real-world persistence and benefit–risk profile of fingolimod over 36 months in Germany
por: Ziemssen, Tjalf, et al.
Publicado: (2019)

Siponimod Inhibits the Formation of Meningeal Ectopic Lymphoid Tissue in Experimental Autoimmune Encephalomyelitis
por: Brand, Rosa Margareta, et al.
Publicado: (2021)

Real-world evidence on siponimod treatment in patients with secondary progressive multiple sclerosis
por: Regner-Nelke, Liesa, et al.
Publicado: (2022)

Fingolimod promotes peripheral nerve regeneration via modulation of lysophospholipid signaling
por: Szepanowski, Fabian, et al.
Publicado: (2016)

Spotlight on siponimod and its potential in the treatment of secondary progressive multiple sclerosis: the evidence to date
por: Gajofatto, Alberto
Publicado: (2017)

Efficacy and safety of siponimod for multiple sclerosis: Protocol for a systematic review and meta-analysis
por: Song, Yumeng, et al.
Publicado: (2019)

Siponimod ameliorates metabolic oligodendrocyte injury via the sphingosine-1 phosphate receptor 5
por: Behrangi, Newshan, et al.
Publicado: (2022)

First in vivo fluorine-19 magnetic resonance imaging of the multiple sclerosis drug siponimod
por: Starke, Ludger, et al.
Publicado: (2023)

Anti-inflammatory Effects of Siponimod in a Mouse Model of Excitotoxicity-Induced Retinal Injury
por: Basavarajappa, Devaraj, et al.
Publicado: (2023)

Peripheral Blood T Cell Dynamics Predict Relapse in Multiple Sclerosis Patients on Fingolimod
por: Song, Zi-Ye, et al.
Publicado: (2015)

Fingolimod therapy is not effective in a mouse model of spontaneous autoimmune peripheral polyneuropathy
por: Huehnchen, Petra, et al.
Publicado: (2018)

Treatment satisfaction and quality of life in patients treated with fingolimod
por: Mékiès, Claude, et al.
Publicado: (2018)

Cost-effectiveness and budget impact analysis of siponimod in the treatment of secondary progressive multiple sclerosis in Italy
por: Cortesi, Paolo Angelo, et al.
Publicado: (2022)

Pharmacokinetic Characteristics of Siponimod in Healthy Volunteers and Patients With Multiple Sclerosis: Analyses of Published Clinical Trials
por: Chaoyang, Chen, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5hor677m17b11ir7juoiqaa6tn